Defining the pathology underlying cortico-basal syndrome: A European study
Objective: To understand how clinical and biological features can help us define and explain the varying pathology that underlies corticobasal syndrome (CBS). Background: Corticobasal degeneration…Low cerebrospinal fluid 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol levels are biomarkers of Parkinsonian disorders, including PSP
Objective: To assess whether Progressive Sopranuclear Palsy (PSP) patients show, in CSF an alteration of catecholamine metabolites. Background: It was reported previously that, consistent with…Allele specificity in neurodegenerative olfactory dysfunction
Objective: Assess olfactory dysfunction in carriers of the p.N279K and p.P301L MAPT mutations, which cause FTDP-17, to understand how genotypic differences contribute to the severity…Analysis of MAPT, GRN and C9orf72 genes in progressive supranuclear palsy, corticobasal syndrome and frontotemporal lobar degeneration in Russian population
Objective: To investigate MAPT variants and haplotypes, GRN mutations, and C9orf72 expansion in a cohort of Russian patients with progressive supranuclear palsy (PSP), cotricobasal syndrome…A pilot study of whole exome sequencing in progressive supranuclear palsy
Objective: To identify genetic variants associated with Progressive Supranuclear Palsy (PSP) using whole exome sequencing. Background: PSP is a rare tauopathy but is the second…High throughput pooled-DNA sequencing of mendelian/susceptibility Parkinson’s disease genes in Spanish population
Objective: The primary outcome of our study was the identification of rare variants in 5 major Mendelian PD genes (SNCA, PARK2, PINK1, DJ1, LRRK2) and…Phosphorylation by GSK-3β enhances binding of metal ion induced tau oligomers to neutral lipid surfaces
Objective: To dissect the complex interplay of tau hyperphosphorylation, metal ion induced oligomer formation and membrane interactions applying single particle fluorescence techniques. Background: Fibrillar deposits…THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy
Objective: The objective of our study is to investigate characteristics of THK-5351 binding in patients with clinically diagnosed progressive supranuclear palsy (PSP) and correlate tau-tracer…Tau PET in Parkinson syndromes. A new diagnostic tool?
Objective: To explore the potential of [F-18]-AV-1451 PET as a diagnostic tool in Parkinson plus syndromes. Background: Clinically, atypical Parkinson syndromes are often difficult to…[18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease
Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.